Mahbouba Jguirim

Mahbouba Jguirim

Auto-generated profile, based on publicly available information

Mahbouba Jguirim

Department of Rheumatology, University Hospital F.B., University of Monastir, Tunisia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
MEMourad ElGhali
Mourad ElGhali
MMMariem Mhiri
Mariem Mhiri
ICImene Chaabane
Imene Chaabane
WMWafa Marrakchi
Wafa Marrakchi
RKRania Kaddoussi
Rania Kaddoussi
NSNabil Sakly
Nabil Sakly
Elghali M, et al. Clin Exp Vaccine Res. 2025 Jul;14:e34. https://doi.org/10.7774/cevr.2025.14.e34

23 February 2025 in Rheumatology
Verified
Journal Article
Open access
MEMourad ElGhali
Mourad ElGhali
BYBoussoukaya Yosr
Boussoukaya Yosr
DSDaadaa Syrine
Daadaa Syrine
JMJguirim Mahbouba
Jguirim Mahbouba
NSNabil Sakly
Nabil Sakly
Sonia HammamiSonia Hammami
Sonia Hammami
Introduction: The aim of the study was to compare the specific clinical manifestations of systemic lupus erythematosus (SLE) or laboratory findings between patients with and without anti-ribosomal P (anti-P) antibodies and to investigate possible associations between isolated anti-P antibodies and these features.Material and methods: Seventy-five SLE patients were enrolled in this study. They were recruited from the Department of Internal Medicine and Department of Rheumatology at the University Hospital of Monastir, Tunisia (January 2008 – December 2022). All patients met at least four American College of Rheumatology criteria or Systemic Lupus Erythematosus International Collaborating Clinics criteria at the time of disease diagnosis. Antibody typing was performed using a commercial line blot technique. Statistical analysis was performed using the χ2 test, Fisher’s test when appropriate, Student’s t-test, or Mann-Whitney U test according to normality of the data distribution.Results: Thirty patients (40%) were positive for anti-P (anti-P+). The anti-P+ had higher frequency of skin features (26/49 [53.1%] vs. 4/26 [15.4%], p = 0.003) and central nervous system (CNS) involvement (10/15 [66.7%] vs. 20/60 [33.3%], p = 0.018) than patients without anti-P. Interestingly, anti-P+ showed a lower frequency of SLE/rheumatoid arthritis overlap syndrome (1/11 [9.1%] vs. 29/64 [45.3%], p = 0.042). The comparison between groups of patients according to the presence of anti-P, anti-dsDNA, and anti-Sm showed that the group with anti-P lacking anti-dsDNA and anti-Sm had the highest frequency of neuropsychiatric SLE (75%, p = 0.034), and the lowest frequency of lupus nephritis (0%, p = 0.029) and arthritis (12.5%, p = 0.039).Conclusions: This study supports the association of anti-P antibodies with CNS and cutaneous mani­festations. To the best of our knowledge, this is the first study to report a negative association between isolated anti-P antibodies and renal and articular involvement in SLE.

1 June 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MJM. Jguirim
M. Jguirim
AMA. Mhenni
A. Mhenni
WMW. Mnari
W. Mnari
LML. Mani
L. Mani
SZS. Zrour
S. Zrour
NBN. Bergaoui
N. Bergaoui
Background Hip involvement is a common but little studied feature of spondyloarthritis (SpA). Objectives The aim of the present paper is to study the prevalence, clinical and radiological features of hip involvement, and the association with criteria for severity, in a cohort of patients with SpA. Methods Study design: retrospective single center observational study between 2010 and 2013. Patients: definite SpA (Amor's criteria). Data collection: prevalence of hip involvement, and if present, the date of appearance, the localization and nature of the pain, treatments performed (intra-articular injections, surgery) and outcomes of total joint replacement (TJR). Analysis: descriptive analysis. Results 152 consecutive SpA patients were assessed: 42/152 patients (27%) suffered from SpA-associated hip involvement; median age 32.38±13.5 (range 14–74) years, median symptom duration 8.24±6.3 years, 33 (78.6%) were men. None patient with hip involvement had been treated by anti TNF at data collection. Hip involvement appeared during the first 3 years of disease duration in 78%. The median Lequesne score of the hip was 17.3±3.59 [11-22]. The BASDAI was at 5.47±1.93 and the BASRI was at 6.5±3 [2-6]. Prevalence varied according to SpA predominant manifestation: more frequent in axial patients (32 patients, 76.6%), than in peripheral disease. The features of hip involvement were pseudoarthrosic in 61.9% (26 patients), destructrive or pseudorhumatoid in 10 patients (23.8%), contrictive in 5 cases (11.9%) and synostosant in 1 patient (2.4%). Hip involvement was bilateral in 50% (21/42). 23 patients (54.8%) received intra articular corticoid injections (of which, 4.8% were triamcinolone hexacetonide, and acide osmique in the other cases). 16 patients (38.1%) have one synoviorthesis, 6 (14.3%) have two and one patient had underwent three synoviorthesis. In all, 6 patients (6% of the whole group and 14.3% of patients with hip involvement) had a TJR. TJR was unilateral in 5 patients and bilateral in one case. The median delay between first hip symptoms and TJR was 47 months (range 0–29 years). After a median follow-up of TJR of 101 months (range 2– 27 years), TJR was considered as having a immediate good function in 100% and only 16% (1/6) patients had TJR complications with a second TJR of the hip. Conclusions Hip involvement is a frequent manifestation in SpA (X %), often bilateral, and associated with non-Caucasian origin. One third of the patients needed total joint replacement. Physicians should be wary of hip pain in SpA patients and implement rapid diagnostic procedures in such cases. References Burki V1, Gossec L, Payet J, Durnez A, Elhai M, Fabreguet I and al. Prevalence and characteristics of hip involvement in spondyloarthritis: a single-centre observational study of 275 patients. Clin Exp Rheumatol. 2012;30:481-6. Disclosure of Interest None declared

1 June 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
HMH Mouanaa
H Mouanaa
ZSZ Saoussen
Z Saoussen
AAA Arfa
A Arfa
MJM Jguirim
M Jguirim
IBI Bejia
I Bejia
NBN Bergaoui
N Bergaoui
Background Osteomalacia is a defect of mineralization of the protein framework of the skeleton. Objectives We try through our series to determine the presentation modalities and the various causes of this fragile benign osteopathy. Methods It is a descriptive retrospective study of cases collected in our rheumatology department between 2001 and 2016, concerning patients with osteomalacia Results Twenty patients were collected: 13 women and 7 men with an average age of 53±19 years [22 years, 80 years]. The mean duration of the disease is 45 months [5–172]. The findings were: bone pain in 55% of cases, pelvic pain in 45% of cases, a waddling gait in 5 cases (25%), fractures with low energy in 40% of cases, Functional impotence of the lower limbs in 35% of cases and a biological discovery in 2 cases (10%). Hypocalcemia, phosphorus deficiency and hypocalciuria were found in 14 cases, ie 70%. Alkaline phosphatases were elevated in 12 cases, with a variable rate of 2 to 7 times normal.The PTH, performed in 17 cases, was elevated in 53% of the cases. In our series, all patients had hypovitaminosis D. In addition, an associated iron deficiency anemia was detected in 50% of the cases, biological stigma of digestive malabsorption in 40% of the cases and renal insufficiency in 15% of the cases. Standard radiographs showed diffuse demineralization in 90% of cases, Looser-Milkman streaks in 40% of cases and fractures in 30% of cases. Bone scintigraphy among 8 patients revealed diffuse hyperfixation in 4 cases (50%), localized hyperfixation in 3 cases (37%) and non conclusive images in only one case (12.5%). Bone densitometry performed in 5 patients showed secondary osteoporosis in 80% of cases. The diagnosis of osteomalacia was retained in 2 cases, celiac disease in 5 cases, renal insufficiency in 1 case, phosphate diabetes in 3 cases including Fanconi syndrome, hypophosphatasia in one case and tubular involvement as part of ankylosing spondylitis In one case. Etiology was a neoplastic cause in 4 cases including multiple myeloma. All the patients had a vitamin-calcium treatment (calcium intake between 500mg and 2g per day with an average of 2.5 cp/d, phosphorus in 3 cases and an etiological treatment in 3 cases. The resection of the tumor was the reason behind a clinical-biological improvement in the case of thyroid tumors. The outcome was favorable in the short term for all cases. Conclusions Osteomalacia is a generalized benign osteopathy, essentially linked to a deficiency in vitamin D often unrecognized. The diagnosis is simple and the treatment is easy, but the ignorance of the etiological forms can be responsible for an unfavorable evolution. Disclosure of Interest None declared

1 March 2015 in Revue du Rhumatisme
Verified
Journal Article
Closed access
JMJguirim Mahbouba
Jguirim Mahbouba
MAMhenni Amira
Mhenni Amira
MWMnari Walid
Mnari Walid
MTMongi Touzi
Mongi Touzi
BNBergaoui Naceur
Bergaoui Naceur